OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Michael D. Lam
Analysts and consultants dip into the pipeline to select 25 products that are going to make a difference for pharma—and patients.
Will this be the year drug importation staggers the industry? Will the sales force keep growing? What's next in technology? Our panel of prophets answer these questions and more.
Unleash the Dragonc
All those patients. All those scientists. And all those US-trained entrepreneurs looking for partners. No wonder pharma is increasingly turning to China.
Conflict Resolution: A Pharm Exec Conference Report
New standards for pharma-supported medical education aren't as impossible as they seem. ACCME's Murray Kopelow explains why.
The Ethics of Pharma
A Pharm Exec Roundtable
If ethics were just about telling wrong from right, it would be hard enough. The trickiest part, these experts say, is choosing between right and right.
The managed-care backlash is easing
Would you enroll your child in a clinical trial?
Mark Scheineson, a former FDA official, urges pharma companies to contest class-action suits aggressively.
Bush's re-election was good news for pharma, but there are still some important issues for the next four years.
In Britain, a new law lops another 7 percent off drug prices—by setting limits on profits.
Some courts are rejecting "grouping" of lawsuits against pharma. Here's why that's good news.
William M. Janssen
Saul Ewing LLP
Every day you get to choose the attitude you'll take. To succeed, choose persistence.
Sander A. Flaum
Direct to Consumer
It's cheap, targeted, and mobile, and people spend 20 hours a week listening to it. Remember radio?
Interep Innovations Marketing Group
Electronic medical records can enhance physician involvement in patient adherence.
Devin S. Paullin and Paul Foley
Allscripts Healthcare Solutions
Marketing to Professionals
It's true—you can measure the performance of a medical science liaison.
Medical Science Liaison Institute
Weakness in equity markets means that executives are making a beeline for the buy side. What's your strategy?
Citigate Financial Intelligence
Have you checked all the basics? Check'em again.
Melissa R. Dull and Lynnell R. Wakley
From the Editor
We all want safe drugs, even when we demand risky ones. That's consistent, right?
Can Vioxx be the catalyst to change how we manage risk?
Murray L. Aitken
Calendar of Events